It is well recognized that angiogenesis, the growth of new blood vessels from preexisting vasculature, plays a fundamental role in health and disease. For the discovery of new drugs targeting the vasculature, it is common practice to use primary endothelial cells in culture systems. However, a number of constraints impede their routine application in drug discovery.
To meet the demands of predictive preclinical vascular drug research, improved in vitro models of the vasculature are required: models that are amenable to high-throughput screening, with a scalable and robust cell source, in a physiological relevant cellular micro-environment. Human induced pluripotent stem cell (iPSC)-derived cells are promising candidates to fulfil these requirements.
We have developed a reproducible manufacturing process for the generation of large numbers of iPSC-derived endothelial cells, using a set of controlled bioreactor systems, and used them to develop an angiogenesis assay which is compatible with high-content imaging and high-throughput screening.
Download the poster to learn more:
Download the poster by filling the form below: